HALOZYME THERAPEUTICS, INC. 8-K

What Happened
Halozyme Therapeutics, Inc. filed an 8-K on April 30, 2026 announcing that Darren Snellgrove (age 52) will join as Chief Financial Officer effective June 8, 2026. Mr. Snellgrove joins from Johnson & Johnson, where he most recently served as Vice President, Investor Relations (since May 2025) and previously was CFO of J&J’s Pharmaceutical sector (Aug 2021–May 2025). Current Interim CFO David Ramsay will move to an advisory role during a brief transition.

Key Details

• Base salary: $670,000 per year; annual bonus target: 50% of base salary (prorated for 2026).
• Total new-hire equity grant: $7,200,000 (includes $3,200,000 in RSUs and $4,000,000 in stock options).
  • RSU vesting: one-third on each of the first three anniversaries of the grant.
  • Option vesting: 25% after one year, then monthly over the next three years.
• 2027 long-term incentive minimum: $4,000,000 (per Compensation Committee practices).
• Sign-on cash: $350,000 (prorated portion repayable if Mr. Snellgrove leaves voluntarily or is terminated for misconduct within 24 months).
• RSU portion is described as a “make-whole” for forfeited J&J equity after ~27 years of service; awards subject to the Company’s 2021 Stock Plan.

Why It Matters
A permanent CFO hire clarifies Halozyme’s financial leadership and succession after an interim period. The compensation mix—make-whole RSUs plus performance-linked options and a sizable minimum 2027 long-term award—signals the company’s intent to retain an experienced finance executive while aligning a significant portion of pay with future stock performance. Investors should note the near-term cash and equity commitments (salary, sign-on cash, and $7.2M in initial equity) and the vesting conditions that tie value to continued service and share-price appreciation.